The financial opportunity within the antibody drug conjugate market has been analyzed across the following segments:
- Target Disease Indication
- Acute Lymphoblastic Leukemia
- Breast Cancer
- B-Cell Lymphoma
- Cervical Cancer
- Gastric Cancer
- Lung Cancer
- Multiple Myeloma
- Renal Cancer
- Other Target Disease Indications
- Therapeutic Area
- Hematological Cancer
- Solid Tumor
- Linker
- Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)
- Maleimide
- Maleimidocaproyl
- Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate
- Tetrapeptide-Based Linker
- Valine-Alanine
- Valine-Citrulline
- Other Linkers
- Payload
- DM1
- DM4
- Duocarmycin
- Monomethyl auristatin E (MMAE)
- Monomethyl auristatin F (MMAF)
- Ozogamicin
- SG3199
- SN-38 / Irinotecan
- Other Payloads
- Target Antigen
- BCMA (TNFRSF17 / BCM)
- CD19
- CD22
- CD30
- CD79b
- CEACAM5
- HER-2 (ERBB2)
- Nectin 4
- Tissue factor
- TROP-2
- Other Target Antigen
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific and Rest of the World
The Antibody Drug Conjugate Market (7th Edition), 2023-2035 report features the following companies, which we identified to be key players in this domain:
- ADC Therapeutics
- Astellas Pharma
- AstraZeneca
- Byondis
- Daiichi Sankyo
- Genentech
- Gilead Sciences
- ImmunoGen
- Pfizer
- RemeGen
Table of Contents
- Preface
2. Executive Summary
Introduction- Market Landscape
- Target Competitiveness Analysis
- Company and Drug Profiles
- Clinical Trial Analysis
- Key Opinion Leaders
- Combination Therapies
- Partnerships and Collaborations
- Funding and Investment Analysis
- Patent Analysis
- Academic Grants Analysis
- Key Commercialization Strategies
- Promotional Analysis
- Success Protocol Analysis
- Novel Conjugation and Linker Technology Platforms
- Assessment of Non-Clinical Data First in Human Dosing
- Cost Price Analysis
- Case Study 1: Contract Manufacturing of Antibody-Drug Conjugates
- Case Study 2: Companion Diagnostics for Antibody-Drug Conjugate Therapeutics
- SWOT Analysis
- Market Sizing and Opportunity Analysis
- Executive Insights
- Conclusion
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market/270.html
Learn from experts: do you know about these emerging industry trends?
Digital Therapies: The “Digital Pills” of current generation
Medical Device Coatings and Modification Technologies
Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
